Skip to main content
SpringerLink
Log in

Current Therapies for T-cell Lymphomas

  • Chapter
  • First Online:
Non-Hodgkin Lymphoma

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1095 Accesses

Abstract

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. One of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. The International T-cell Lymphoma Project has identified that the outcomes for the majority of the different subtypes of PTCL are poor using conventional lymphoma therapies. Recently, aggressive first-line strategies including consolidation with stem cell transplantation have led to improved survival in selected patients, but the majority of patients either fail to respond to therapy or are not candidates for stem cell transplantation. Novel approaches have included new classes of drug and biological agents, including antifolates, immunoconjugates, histone deacetylase (HDAC) inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signal transduction inhibitors. Molecular profiling has led to identification of relevant pathways for future novel approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. (1997) The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89:3909–3918

    Google Scholar 

  2. Vose J, Armitage J, Weisenburger D et al (2008) The International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  PubMed  Google Scholar 

  3. Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK (2007) Enteropathy-type T-cell lymphoma. Am J Clin Pathol 127:701–706

    Article  PubMed  Google Scholar 

  4. Jung CK, Lee KY, Kim Y et al (2001) Epstein-Barr virus infection, drug resistance and ­prognosis in Korean T- and NK-cell lymphomas. Pathol Int 51:355–363

    Article  PubMed  CAS  Google Scholar 

  5. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR (2008) Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 49:2099–2107

    Article  PubMed  Google Scholar 

  6. Escalon MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 103:2091–2098

    Article  PubMed  Google Scholar 

  7. Mercadal S, Briones J, Xicoy B et al (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958–963

    Article  PubMed  CAS  Google Scholar 

  8. Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–3425

    Article  PubMed  CAS  Google Scholar 

  9. Tilly H, Lepage E, Coiffier B et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284–4289

    Article  PubMed  CAS  Google Scholar 

  10. Delmer A, Fitoussi O, Gaulard P et al (2009) A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1 T trial. ASCO Meeting Abstracts 27:8554

    Google Scholar 

  11. Simon A, Peoch M, Casassus P et al (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the ­randomized phase III trial GOELAMS-LTP95. Br J Haematol 151:159–166

    Article  PubMed  Google Scholar 

  12. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566–567

    Article  PubMed  Google Scholar 

  13. Kim JG, Sohn SK, Chae YS et al (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129–134

    Article  PubMed  CAS  Google Scholar 

  14. Gallamini A, Zaja F, Patti C et al (2007) Alemtuzumab (Campath-1 H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316–2323

    Article  PubMed  CAS  Google Scholar 

  15. Janik JEPS et al (2005) A pilot study of campath-1 with dose-adjusted EPOCH in CD52 expressing aggressive T-cell malignancies. Blood 106:33348

    Google Scholar 

  16. Dang NH, Pro B, Hagemeister FB et al (2007) Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136:439–447

    Article  PubMed  CAS  Google Scholar 

  17. Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED (2010) Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. ASCO Meeting Abstracts 28:8045

    Google Scholar 

  18. Bruns I, Fox F, Reinecke P et al (2005) Complete remission in a patient with relapsed ­angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 19:1993–1995

    Article  PubMed  CAS  Google Scholar 

  19. Advani RH, Hong F, Ganjoo KN et al (2009) Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (avastin) in combination with CHOP (A-CHOP) ­chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 trial. Blood 114:1671 (ASH Annual Meeting Abstracts)

    Google Scholar 

  20. Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860–863

    Article  PubMed  CAS  Google Scholar 

  21. Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92:271–272

    Article  PubMed  CAS  Google Scholar 

  22. Spencer A, Reed K, Arthur C (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 37:760–766

    PubMed  CAS  Google Scholar 

  23. Kim JG, Sohn SK, Chae YS et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58:35–39

    Article  PubMed  Google Scholar 

  24. d’Amore F, Jantunen E, Relander T (2009) Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how? Curr Hematol Malig Rep 4:236–244

    Article  PubMed  Google Scholar 

  25. Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27:106–113

    Article  PubMed  CAS  Google Scholar 

  26. O’Mahony D, Morris J, Moses L et al (2005) Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. Blood 106:937a

    Google Scholar 

  27. O’Mahony D, Morris J, Stetler-Stevenson M et al (2007) EBV-related lymphoproliferative disease complicating therapy with siplizumab, a novel anti-CD2 mediated T- and NK-cell depleting agent, in patients with T-cell malignancies. Blood 110:1043a

    Article  Google Scholar 

  28. Casale D, Bartlett N, Hurd D et al (2006) A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia. Blood 108:771a

    Article  Google Scholar 

  29. d’Amore F, Radford J, Jerkeman M et al (2007) Zanolimumab (HuMax-CD4™), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma. Blood 110:999z

    Google Scholar 

  30. Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18(8):1622–1636

    Article  PubMed  Google Scholar 

  31. Forero-Torres A, Leonard JP, Younes A et al (2009) A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171–179

    Article  PubMed  CAS  Google Scholar 

  32. Ansell SM, Horwitz SM, Engert A et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764–2769

    Article  PubMed  CAS  Google Scholar 

  33. Borchmann P, Treml JF, Hansen H et al (2003) The human anti-CD30 antibody 5 F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102:3737–3742

    Article  PubMed  CAS  Google Scholar 

  34. Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465

    Article  PubMed  CAS  Google Scholar 

  35. Wahl AF, Klussman K, Thompson JD et al (2002) The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 62:3736–3742

    PubMed  CAS  Google Scholar 

  36. Maeda N, Muta H, Oflazoglu E, Yoshikai Y (2010) Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci 101:224–230

    Article  PubMed  CAS  Google Scholar 

  37. Fromm JR, McEarchern JA, Kennedy D, Anju T, Shustov AR, Gopal AK (2010) Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin Lymphoma. Blood 116:1789 (ASH Annual Meeting Abstracts)

    Google Scholar 

  38. Bartlett NL, Younes A, Carabasi MH et al (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111:1848–1854

    Article  PubMed  CAS  Google Scholar 

  39. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  40. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, Aranda A (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10:395–398

    Article  PubMed  CAS  Google Scholar 

  41. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39

    Article  PubMed  CAS  Google Scholar 

  42. Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109–3115

    Article  PubMed  CAS  Google Scholar 

  43. Whittaker SJ, Demierre MF, Kim EJ et al (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485–4491

    Article  PubMed  CAS  Google Scholar 

  44. Piekarz R, Wright J, Frye R et al (2009) Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 114:1657 (ASH Annual Meeting Abstracts)

    Google Scholar 

  45. Pohlman B, Advani R, Duvic M et al (2009) Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood 114:920 (ASH Annual Meeting Abstracts)

    Google Scholar 

  46. Marchi E, Bongero DC, Kalac M, Scotto L, O’Connor OA (2010) The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma. Blood 116:3937 (ASH Annual Meeting Abstracts)

    Google Scholar 

  47. O’Connor OA, Hamlin PA, Portlock C et al (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425–428

    Article  PubMed  Google Scholar 

  48. O’Connor OA, Horwitz S, Hamlin P et al (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357–4364

    Article  PubMed  Google Scholar 

  49. O’Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182–1189

    Article  PubMed  Google Scholar 

  50. Pro B, Coiffier B, Horwitz SM et al (2009) Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: implications for vitamin prophylaxis. Blood 114:1681 (ASH Annual Meeting Abstracts)

    Google Scholar 

  51. Cooper DL, Braverman IM, Sarris AH et al (1993) Cyclosporine treatment of refractory T-cell lymphomas. Cancer 71:2335–2341

    Article  PubMed  CAS  Google Scholar 

  52. Advani R, Horwitz S, Zelenetz A, Horning SJ (2007) Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 48:521–525

    Article  PubMed  CAS  Google Scholar 

  53. Dueck GS, Chua N, Prasad A et al (2009) Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases. ASCO Meeting Abstracts 27:8524

    Google Scholar 

  54. Kurzrock R, Pilat S, Duvic M (1999) Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17:3117–3121

    PubMed  CAS  Google Scholar 

  55. Catovsky D (1996) Clinical experience with 2′-deoxycoformycin. Hematol Cell Ther 38(Suppl 2):S103–S107

    PubMed  CAS  Google Scholar 

  56. Dearden CE (2006) Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas. Semin Hematol 43:S22–S26

    Article  PubMed  CAS  Google Scholar 

  57. Korycka A, Blonski JZ, Robak T (2007) Forodesine (BCX-1777, Immucillin H)–a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 7:976–983

    Article  PubMed  CAS  Google Scholar 

  58. Duvic M, Forero-Torres A, Foss F et al (2006) Oral forodesine is clinically active in refractory cutaneous T-cell lymphoma. Results of a phase I/II study. Blood 108:698a

    Google Scholar 

  59. Zinzani PL, Musuraca G, Tani M et al (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25:4293–4297

    Article  PubMed  CAS  Google Scholar 

  60. Marchi E, Paoluzzi L, Venkatraman SE, O’Connor OA (2008) Pralatrexate (PDX) ­compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid T-cell malignancies. Blood 112:3619

    Google Scholar 

  61. Querfeld C, Rizvi MA, Kuzel TM et al (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126:1641–1647

    Article  PubMed  CAS  Google Scholar 

  62. Fung Leung W (2011) Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 23(4):603–608

    Article  PubMed  CAS  Google Scholar 

  63. Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND et al (2011) Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110δ, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 29:6631

    Google Scholar 

  64. Yamaguchi M, Tobinai K, Oguchi M et al (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594–5600

    Article  PubMed  CAS  Google Scholar 

  65. Lee KW, Yun T, Kim DW et al (2006) First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47:1274–1282

    Article  PubMed  CAS  Google Scholar 

  66. Yong W, Zheng W, Zhu J et al (2006) Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 24:28–32

    Article  PubMed  CAS  Google Scholar 

  67. Yamaguchi M, Suzuki R, Kwong YL et al (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016–1020

    Article  PubMed  CAS  Google Scholar 

  68. Jaccard A, Gachard N, Marin B et al (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood 117:1834–1839

    Article  PubMed  CAS  Google Scholar 

  69. Yamaguchi M, Kwong Y, Maeda Y et al (2010) Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. ASCO Meeting Abstracts 28:8044

    Google Scholar 

  70. Tsukasaki KUA, Fukuda H et al (2007) VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458–5464

    Article  PubMed  CAS  Google Scholar 

  71. Gill PS, Harrington W Jr, Kaplan MH et al (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Eng J Med 332:1744–1748

    Article  CAS  Google Scholar 

  72. Bazarbachi A, Plumelle Y, Carlos Ramos J et al (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28:4177–4183

    Article  PubMed  CAS  Google Scholar 

  73. Yamamoto KUA, Tobinai K et al (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591–1598

    Article  PubMed  CAS  Google Scholar 

  74. Ishida T, Joh T, Uike N et al (2010) Multicenter phase II study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL). Blood 116:285 (ASH Annual Meeting Abstracts)

    Google Scholar 

  75. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  PubMed  Google Scholar 

  76. Jantunen E, Relander T, Lauritzsen GF et al (2010) Intensive induction chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with enteropathy-associated T-cell lymphoma: a prospective study by the nordic lymphoma group (NLG-T-01). Blood 116:3565 (ASH Annual Meeting Abstracts)

    Google Scholar 

  77. Go RS, Wester SM (2004) Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 101:1404–1413

    Article  PubMed  Google Scholar 

  78. Salhany KE, Macon WR, Choi JK et al (1998) Subcutaneous panniculitis-like T-cell ­lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 22:881–893

    Article  PubMed  CAS  Google Scholar 

  79. Kong YY, Dai B, Kong JC et al (2008) Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification. Am J Surg Pathol 32:1495–1502

    Article  PubMed  Google Scholar 

  80. Willemze R, Jansen PM, Cerroni L et al (2008) Subcutaneous panniculitis-like T-cell ­lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111:838–845

    Article  PubMed  CAS  Google Scholar 

  81. Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper DL, Foss F (2008) Outcomes in ­subcutaneous panniculitis-like T-cell Lymphoma (STCL). Blood 112:3750 (ASH Annual Meeting Abstracts)

    Article  Google Scholar 

  82. Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T (2007) Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 48:560–563

    Article  PubMed  CAS  Google Scholar 

  83. Chim CS, Loong F, Ng WK, Kwong YL (2008) Use of fludarabine-containing ­chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell ­lymphoma. Am J Clin Dermatol 9:396–398

    Article  PubMed  Google Scholar 

  84. d’Amore F, Relander T, Lauritzen G et al (2006) Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL) - A phase II study of the Nordic Lymphoma Group (NLG) [ASH abstract 401]. Blood 108(11):123a

    Article  PubMed  Google Scholar 

  85. Jantunen E, Wiklund T, Juvonen E et al (2004) Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Trans 33(4):405–410

    Article  PubMed  Google Scholar 

  86. Smith SD, Bolwell BJ, Rybicki LA et al (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Trans 40(3):239–243

    Article  PubMed  Google Scholar 

  87. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG (2007) Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: The Stanford experience [ASH abstract 1906]. Blood 110(11):566a

    Article  PubMed  Google Scholar 

  88. Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106–113

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Investigations, Hematologic Malignancies, Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, FMP 112, 208032, New Haven, CT, 06520-8032, USA

    Francine M. Foss M.D.

Authors
  1. Francine M. Foss M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine M. Foss M.D. .

Editor information

Editors and Affiliations

  1. Div. Hematology & Oncology, Rhode Island Hospital, Eddy St. 593, Providence, 02903, Rhode Island, USA

    Peter J. Quesenberry

  2. , Division of Hematology and Oncology, The Miriam Hospital, Summit Ave 164, Providence, 02906, Rhode Island, USA

    Jorge J. Castillo

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Foss, F.M. (2013). Current Therapies for T-cell Lymphomas. In: Quesenberry, P., Castillo, J. (eds) Non-Hodgkin Lymphoma. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5851-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5851-7_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5850-0

  • Online ISBN: 978-1-4614-5851-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation